Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMPFIRE
NCT05999994Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2020
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 10
01
Overview
A Phase 2 trial of ramucirumab, abemaciclib in desmoplastic small round cell tumor (DSRCT), synovial sarcoma (SS), Ewing sarcoma, sponsored by Eli Lilly and Company. Started Jan 2020; status: recruiting.
02
Drugs
ramucirumababemaciclib
03
Conditions
desmoplastic small round cell tumor (DSRCT)synovial sarcoma (SS)Ewing sarcoma
Beyond the preview
Go deeper on NCT05999994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999994.